SEC Form 4 · accession 0001209191-19-011999
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 19, 2019 | S | 17,097 | $186.80 | D | 110,095 | D | |
| Common StockF3,F4 | Feb 19, 2019 | S | 2,700 | $187.43 | D | 107,395 | D | |
| Common StockF3,F5 | Feb 19, 2019 | S | 1,200 | $188.61 | D | 106,195 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $187.14 (range $186.16 to $187.14).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $187.43 (range $187.17 to $188.09).
- F5Open market sales reported on this line occurred at a weighted average price of $188.61 (range $188.50 to $188.73).